TMEM100 and non-small cell lung carcinoma: TMEM100 is one example; it presented a “neutral” face in silico, where no Kaplan–Meier split reached significance in either LUAD or LUSC, although multi-database mining (TCGA, GEO, and Oncomine) and IHC showed that TMEM100 is consistently downregulated in tumors versus normal lung tissue, correlating with higher TNM stages and shorter relapse-free survival periods in NSCLC, especially for LUAC.